Federal judge dismisses longstanding suit over Bristol Myers' $74B Celgene buyout
A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to avoid paying out $6.4 billion in contingent …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.